Evidence map›Paper›PMID 38488092›Full record

ArticleClinical and experimental rheumatology2024

Nailfold capillaroscopy findings of a multicentric multi-ethnic cohort of patients with idiopathic inflammatory myopathies.

Jiram Torres-Ruiz, Iago Pinal-Fernandez, Albert Selva-O'Callaghan, Bianca Campbell, Sandra Muñoz-Braceras, Nancy R Mejía-Domínguez, Carlos Núñez-Álvarez, José Milisenda, Maria Casal-Domínguez, Katherine Pak and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Nailfold capillaroscopy in myositis: A case series.SAGE open medical case reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Jiram Torres-Ruiz *Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, and Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Iago Pinal-Fernandez *Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, and Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Albert Selva-O'Callaghan *Systemic Autoimmune Disease Unit, Vall d'Hebron Research Institute, Barcelona, and Universitat Autonoma de Barcelona, Spain.
Bianca Campbell *Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, and Howard University College of Medicine, Washington DC, USA.
Sandra Muñoz-BracerasMuscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Nancy R Mejía-DomínguezRed de Apoyo a la Investigación, Coordinación de Investigación Científica, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Carlos Núñez-ÁlvarezDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
José MilisendaMuscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA, and Muscle Research Unit, Internal Medicine Service, Hospital Clínic de Barcelona, Universidad de Barcelona and CIBERER, Barcelona, Spain.
Maria Casal-DomínguezMuscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Katherine PakMuscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Alfredo Guillén-Del-CastilloSystemic Autoimmune Disease Unit, Vall d'Hebron Research Institute, Barcelona, Spain.
Ernesto Trallero-AraguasRheumatology Department, Vall d'Hebron Research Institute, Barcelona, Spain.
Albert Gil-VilaSystemic Autoimmune Disease Unit, Vall d'Hebron Research Institute, Barcelona, Spain.
Andrew Lee MammenMuscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulations, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore; and Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. andrew.mammen@nih.gov.
National Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Institutes of Health · USVall d'Hebron Hospital Universitari · ESInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXJohns Hopkins Medicine · USUniversidad Nacional Autónoma de México · MXUniversitat Autònoma de Barcelona · ESVall d'Hebron Institut de Recerca · ES

Funding

Intramural NIH HHS Z99 AR999999
6 · The paper itself

Abstract

objectivesTo assess nailfold video capillaroscopic (NVC) abnormalities and their association with clinical features, myositis-specific autoantibodies (MSA), and myositis-associated antibodies (MAA) in a large multi-ethnic cohort of patients with idiopathic inflammatory myopathies (IIM).

methodsWe recruited 155 IIM patients from three centres in Mexico, Spain, and the USA. We evaluated the clinical and laboratory features of the patients and performed semiquantitative and quantitative analyses of the NVC. Each NVC study was defined as having a normal, non-specific, early systemic sclerosis (SSc), active SSc, or late SSc pattern. Twenty-three patients had at least one follow-up NVC when disease control was achieved. Quantitative variables were expressed as medians and interquartile range (IQR) and were compared with the Kruskal-Wallis, the Mann-Whitney U-test, and the Wilcoxon test for paired medians. Associations between qualitative variables were assessed with the χ2 test.

resultsMost patients were women (68.3%), Hispanic (73.5%), and had dermatomyositis (DM) (61.2%). Fourteen patients (9%) had a normal NVC. A non-specific abnormality pattern was the most frequent (53.9%), and was associated with joint involvement, interstitial lung disease, Jo1 autoantibodies, anti-synthetase syndrome, and immune-mediated necrotising myopathy. The SSc pattern was observed mostly in DM and overlap myositis and was associated with cutaneous features and anti-TIF-1g autoantibodies. After treatment, there was a decrease in the capillaroscopic score, the capillary diameter, and the number of avascular areas, and an increase in capillary density and bushy capillary number.

conclusionsNVC abnormalities are related to the diagnosis, clinical features, disease activity, and autoantibodies of patients with IIM.

Indexed as

MyositisScleroderma, SystemicAutoantibodiesCapillariesFemaleHumansMaleMicroscopic AngioscopyNailsAutoantibodies

Identifiers

PMID38488092
PMCPMC11669110
OpenAlexW4392798893

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.